Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Explore this paper's citation graph
Summary
Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes, and DPP-4 inhibition with saxgliptin did not increase or decrease the rate of ischemic events, though the rates of hospitalization for heart failure was increased.
- Type
- article
- Published
- 2013-10-02
- Cited by
- 3,249
- References
- 43
- Access
- Open access
- OpenAlex
- https://openalex.org/W2064130493
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:5080046
Keywords
Saxagliptin, Medicine, Hazard ratio, Myocardial infarction, Internal medicine
References
- Effects of intensive glucose lowering in type 2 diabetes.
- Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
- Basal insulin and cardiovascular and other outcomes in dysglycemia.
- Review of an article: The ADVANCE Collaborative Group. (2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM 2008;358:2560-2572.
- Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.
- Cardiovascular effects of gliptins
- Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61
- The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- Debate: CON Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?
- Heart Disease and Stroke Statistics—2013 Update
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies
- Standards of medical care in diabetes.
- Trends in All-Cause and Cardiovascular Disease Mortality among Women and Men with and without Diabetes in the Framingham Heart Study, 1950-2005
- Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
- New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
- Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
- Incretin Therapy and Islet Pathology: A Time for Caution
Cited by
- Hypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2
- Incretin-Based Therapies: Facing the Realities of Benefits Versus Side Effects
- Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
- A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)
- Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?
- Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?
- Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up
- Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
- Management of Hyperglycemia in Diabetic Kidney Disease
- First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus
- Sitagliptin and other ‘gliptins’– why prescribe them?
- Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
- Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
- Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
- SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?
- Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes
- Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink
- Context-dependent effects of dipeptidyl peptidase 4 inhibitors
- Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
- Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
Related papers
- Appraisal of Saxagliptin as Treatment of Type 2 Diabetes
- Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus
- The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
- 2 型糖尿病患者における新規 DPP－4 阻害薬サキサグリプチンの有用性―国内で行われた臨床試験を中心に―
- Saxagliptin: New Therapy for Type 2 Diabetes
- Saxagliptin: A Review in Type 2 Diabetes
- [Efficacy of Saxagliptin for Blood Glucose Control in Hemodialysis Patients with Diabetes].
- Saxagliptin a New Second Line Therapy After Metformin for the Treatment of Type 2 Diabetes
- Combined anti-platelet treatment in 221 patients with unstable angina